These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31015814)

  • 41. Summary of the National Advisory Committee on Immunization (NACI) Updated Guidance on Influenza Vaccination During Pregnancy.
    Siu W; Sinilaite A; Papenburg J
    Can Commun Dis Rep; 2024 Apr; 50(3-4):86-92. PubMed ID: 38716409
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Summary of the National Advisory Committee on Immunization's Update on quadrivalent meningococcal vaccines available in Canada.
    Henry B;
    Can Commun Dis Rep; 2015 Apr; 41(Suppl 3):17-18. PubMed ID: 29769963
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age.
    Haas H; Richard P; Eymin C; Fiquet A; Kuter B; Soubeyrand B
    Hum Vaccin Immunother; 2019; 15(4):778-785. PubMed ID: 30481110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Summary of the NACI Statement on Seasonal Influenza Vaccine for 2017-2018.
    Vaudry W; Stirling R;
    Can Commun Dis Rep; 2017 May; 43(5):96-103. PubMed ID: 29770072
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T; McIntyre P; Roberton D; Descamps D
    Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Feasibility of identifying plasma donors with high measles neutralizing antibody concentrations for the use of producing a measles hyperimmune globulin for postexposure prophylaxis.
    Lackner C; Karbiener M; Faltner L; Farcet MR; Kreil TR
    Immunol Res; 2022 Jun; 70(3):365-370. PubMed ID: 35266077
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial.
    Li Y; Chu SY; Yue C; Wannemuehler K; Xie S; Zhang F; Wang Y; Zhang Y; Ma R; Li Y; Zuo Z; Rodewald L; Xiao Q; Feng Z; Wang H; An Z
    Lancet Infect Dis; 2019 Apr; 19(4):402-409. PubMed ID: 30833160
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Summary of NACI Statement: Interim Recommendations on the Use of Pneumococcal Vaccines in Immunocompetent Adults 65 Years of Age and Older.
    Quach C; Baclic O;
    Can Commun Dis Rep; 2016 Dec; 42(12):260-262. PubMed ID: 29769998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP) Recommended Immunization Schedule (2018-19) and Update on Immunization for Children Aged 0 Through 18 Years.
    Balasubramanian S; Shah A; Pemde HK; Chatterjee P; Shivananda S; Guduru VK; Soans S; Shastri D; Kumar R;
    Indian Pediatr; 2018 Dec; 55(12):1066-1074. PubMed ID: 30745480
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices.
    Rupprecht CE; Briggs D; Brown CM; Franka R; Katz SL; Kerr HD; Lett SM; Levis R; Meltzer MI; Schaffner W; Cieslak PR;
    MMWR Recomm Rep; 2010 Mar; 59(RR-2):1-9. PubMed ID: 20300058
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age.
    Vesikari T; Becker T; Gajdos V; Fiquet A; Thomas S; Richard P; Baudin M
    Vaccine; 2012 Apr; 30(20):3082-9. PubMed ID: 22406278
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunosuppression Does Not Affect Antibody Concentrations to Measles, Mumps, and Rubella in Patients with Inflammatory Bowel Disease.
    Caldera F; Misch EA; Saha S; Wald A; Zhang Y; Hubers J; Megna B; Ley D; Reichelderfer M; Hayney MS
    Dig Dis Sci; 2019 Jan; 64(1):189-195. PubMed ID: 30317494
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rabies post-exposure prophylaxis: A systematic review on abridged vaccination schedules and the effect of changing administration routes during a single course.
    Kessels J; Tarantola A; Salahuddin N; Blumberg L; Knopf L
    Vaccine; 2019 Oct; 37 Suppl 1():A107-A117. PubMed ID: 30737043
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
    Lalwani S; Chatterjee S; Balasubramanian S; Bavdekar A; Mehta S; Datta S; Povey M; Henry O
    BMJ Open; 2015 Sep; 5(9):e007202. PubMed ID: 26362659
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of hepatitis A vaccine in post-exposure prophylaxis, The Netherlands, 2004-2012.
    Whelan J; Sonder GJ; Bovée L; Speksnijder A; van den Hoek A
    PLoS One; 2013; 8(10):e78914. PubMed ID: 24147144
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.
    Yadav S; Thukral R; Chakarvarti A
    Indian J Med Res; 2003 Nov; 118():183-6. PubMed ID: 14723482
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.